Additionally, 45.1% of those individuals are classified as overweight.[9] GLP-1 RAs are now considered a cornerstone in effective obesity management protocols.[10] This is supported by wide-ranging evidence from randomized controlled trials and meta-analyses.[11] The use of GLP-1 RAs is associated with weight loss of 4 to 16 kg.[11,12] Moreover, treatment guidelines recommend these medications as first-line therapy among various patient groups, specifically those with comorbid conditions.[13]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.